Search

Displaying results 2681 - 2690 of 10000 in total
  1. Drug

    Diphemanil

    go.drugbank.com/drugs/DB13720
    ApprovedVet approvedWithdrawn

  2. Drug

    BG-777

    go.drugbank.com/drugs/DB05839
    Experimental

    BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.

  3. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting

  4. Drug

    Cobomarsen

    go.drugbank.com/drugs/DB14931
    Investigational

    Cobomarsen is under investigation in clinical trial NCT02580552 (Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL).

  5. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    It is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day. … It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambert–Eaton myasthenic syndrome (LEMS), has been investigated in the 1980s [L3171

  6. Drug

    Alverine

    go.drugbank.com/drugs/DB01616
    ApprovedInvestigationalWithdrawn

    It is therefore useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain.

    Mixtures: METEOSPASMYL 60 MG/300 MG YUMUŞAK KAPSÜL, 40 KAPSÜLSynonyms: Di(phenylpropyl)ethylamine, N,N-Bis(3-phenylpropyl)ethylamine
  7. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    Gonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. … FDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803]

  8. Drug

    Talazoparib

    go.drugbank.com/drugs/DB11760
    ApprovedInvestigational

    [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020. … [L47301] Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306]

    Products: TALZENNA CAPSULE 1MG, Talzenna 1mg Hard Capsules
  9. Drug

    Sodium carbonate

    go.drugbank.com/drugs/DB09460
    ApprovedWithdrawn

    When dissolved in water, sodium carbonate forms carbonic acid and sodium hydroxide. As a strong base, sodium hydroxide neutralizes gastric acid thereby acting as an antacid.

    Mixtures: Sel De Perou, SAL DE FRUTAS PHILLIPS DOBLE ACCION
  10. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    efficacy of a 2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … S1P receptors are membrane-derived lysophospholipid signaling molecules that are involved in the sequestration of circulating peripheral lymphocytes in lymph nodes.